Key Laboratory of Hunan Province for Study and Utilization of Ethnic Medicinal Plant Resources, College of Biological and Food Engineering, Huaihua University, Huaihua, 418008, China.
Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, 43210, USA.
Sci Rep. 2019 Jul 8;9(1):9805. doi: 10.1038/s41598-019-46052-8.
mTOR signaling pathway is deregulated in most cancers and uncontrolled cell cycle progression is a hallmark of cancer cell. However, the precise molecular mechanisms of the regulation of DNA replication and chromatin metabolism by mTOR signaling are largely unknown. We herein report that mTOR signaling promotes the loading of MCM2-7 helicase onto chromatin and upregulates DNA replication licensing factor CDC6. Pharmacological inhibition of mTOR kinase resulted in CHK1 checkpoint activation and decreased MCM2-7 replication helicase and PCNA associated with chromatins. Further pharmacological and genetic studies demonstrated CDC6 is positively controlled by mTORC1-S6K1 and mTORC2 signaling. miRNA screening revealed mTOR signaling suppresses miR-3178 thereby upregulating CDC6. Analysis of TCGA data found that CDC6 is overexpressed in most cancers and associates with the poor survival of cancer patients. Our findings suggest that mTOR signaling may control DNA replication origin licensing and replisome stability thereby cell cycle progression through CDC6 regulation.
mTOR 信号通路在大多数癌症中失调,细胞周期失控是癌细胞的标志。然而,mTOR 信号对 DNA 复制和染色质代谢的调控的精确分子机制在很大程度上尚不清楚。本文报道 mTOR 信号促进了 MCM2-7 解旋酶加载到染色质上,并上调了 DNA 复制起始因子 CDC6。mTOR 激酶的药理学抑制导致 CHK1 检查点激活,并减少与染色质相关的 MCM2-7 复制解旋酶和 PCNA。进一步的药理学和遗传学研究表明,CDC6 受到 mTORC1-S6K1 和 mTORC2 信号的正向调控。miRNA 筛选显示,mTOR 信号抑制 miR-3178,从而上调 CDC6。TCGA 数据分析发现,CDC6 在大多数癌症中过度表达,并与癌症患者的不良预后相关。我们的研究结果表明,mTOR 信号可能通过调控 CDC6 来控制 DNA 复制起始点的许可和复制体的稳定性,从而促进细胞周期进程。